Keymed Biosciences Co.Ltd Drug Pipeline

Keymed Biosciences Co.Ltd maintains a substantial clinical portfolio, with 29 active trials out of 53 total registered since 2008. The pipeline spans early- to late-stage development, comprising 10 active Phase 1 trials, 20 in Phase 2, and 5 in Phase 3. Therapeutic focus is distributed across five areas, with a notable concentration in immunology, which accounts for 21% of active programs. Within immunology, the leading indication is atopic dermatitis, with five active trials, including three in Phase 3. Other key therapeutic areas include oncology, with four active trials, and respiratory diseases, with three. Rare diseases and central nervous system disorders each have two active trials. The relatively high number of Phase 3 trials in atopic dermatitis suggests a potential near-term focus on bringing new therapies to market in this indication.